In recent studies headed by Dr Mark Guthridge in the Leukemia Research Laboratory at the Australian Centre for Blood Diseases, Monash University and published in PLOS Biology, a new role was identified for the protein kinase activity of PI3K in regulating the “survival-only” response of human hematopoietic (blood) cells. These studies provide the first evidence that the protein kinase activity of PI3K can control cell survival and that this activity is a therapeutic target in cancer.
